Dr. Ann H. Partridge

• 
  www.mamm.com/highlights.php?&qbackid=480f75c343300ce8_1 - [Cached Version]
  Published on: 5/9/2008    Last Visited: 5/9/2008  

  That's not clear, says lead author Ann Partridge, M.D., M.P.H., a medical oncologist at Dana-Farber Cancer Institute in Boston."Are women with higher anxiety more likely to misunderstand their risk, or are women somehow developing inaccurate risk perceptions and then developing anxiety?I'm not sure," she says.
  ...
  A strong relationship between a patient and her medical team is essential in making choices on care, Partridge says.

• 
  www.forwoman.org/news/english/619586.htm - [Cached Version]
  Published on: 9/24/2008    Last Visited: 10/3/2008  

  "They have debunked the commonly held belief that age alone is a risk factor for recurrence after treatment of DCIS," said Dr. Ann Partridge, a medical oncologist and researcher at the Dana-Farber Cancer Institute and Brigham and Women's Hospital, in Boston.
  
  Partridge has published about women's anxiety over their prognosis when diagnosed with a DCIS.She found that women are typically highly anxious, even though their risk of recurrence or of developing invasive breast cancer is low.
  
  "I think this is a good study," Partridge said, although it does have limitations.For instance, she said, it is a single-institution study.However, Fox Chase physicians "are doing what they should be doing," Partridge said, explaining that the institution is careful about selecting the right treatment for the right patients, based on the characteristics of their cancer.
  
  More information
  
  There's more on DCIS at breastcancer.org.
  
  SOURCES: Aruna Turaka, M.D., fellow, department of radiation oncology, Fox Chase Cancer Center, Philadelphia; Ann Partridge, M.D., medical oncologist and researcher, Dana-Farber Cancer Institute and Brigham & Women's Hospital, Boston; Sept. 24, 2008, presentation, American Society for Therapeutic Radiology and Oncology annual meeting, Boston

• 
  www.insidermedicine.com/archives/Forty-five_Percent_of_ - [Cached Version]
  Published on: 1/4/2008    Last Visited: 3/8/2008  

  In the Clinic - Dr. Ann Partridge, MD, MPH on assessing a breast lump

• 
  www.washoehealth.com/body.cfm?id=925&action=detail&aepr - [Cached Version]
  Published on: 10/7/2008    Last Visited: 9/25/2008  

  "They have debunked the commonly held belief that age alone is a risk factor for recurrence after treatment of DCIS," said Dr. Ann Partridge, a medical oncologist and researcher at the Dana-Farber Cancer Institute and Brigham and Women's Hospital, in Boston.
  
  Partridge has published about women's anxiety over their prognosis when diagnosed with a DCIS.She found that women are typically highly anxious, even though their risk of recurrence or of developing invasive breast cancer is low.
  
  "I think this is a good study," Partridge said, although it does have limitations.For instance, she said, it is a single-institution study.However, Fox Chase physicians "are doing what they should be doing," Partridge said, explaining that the institution is careful about selecting the right treatment for the right patients, based on the characteristics of their cancer.
  
  More information
  
  There's more on DCIS at breastcancer.org.
  
  SOURCES: Aruna Turaka, M.D., fellow, department of radiation oncology, Fox Chase Cancer Center, Philadelphia; Ann Partridge, M.D., medical oncologist and researcher, Dana-Farber Cancer Institute and Brigham & Women's Hospital, Boston; Sept. 24, 2008, presentation, American Society for Therapeutic Radiology and Oncology annual meeting, Boston

• 
  www.eurekalert.org/pub_releases/2008-02/jotn-po020708.p - [Cached Version]
  Published on: 2/7/2008    Last Visited: 2/12/2008  

  Ann Partridge, M.D., and colleagues at Dana-Farber Cancer Institute in Boston investigated perceived breast cancer risks among women with newly diagnosed DCIS and how these risk perceptions were associated with anxiety and depression.

• 
  myecare.sharp.com/news/index.cfm?id=10122 - [Cached Version]
  Published on: 10/7/2008    Last Visited: 7/9/2008  

  "Many of these women are living as if they're waiting for the other shoe to drop," says lead researcher Dr. Ann Partridge, an oncologist at the Dana-Farber Cancer Institute in Boston.
  ...
  The choice of treatment depends upon the characteristics of the patient and the lesion, adds Dr. Partridge.
  
  The dilemma posed by the prospect of under- or overtreating DCIS is complicated by medicine's current inability to distinguish between "good actors and bad actors" - lesions that do not recur or go on to become invasive breast cancer and those that do, she adds.

• 
  www.pri-med.com/pmo//ViewEvent.aspx?EventCode=47LAX08A - [Cached Version]
  Published on: 9/26/2008    Last Visited: 9/26/2008  

  Ann H. Partridge, MD, MPH, Breast Oncology Center, Dana-Farber Cancer Institute, Boston, MA, Assistant Professor of Medicine, Harvard Medical School, Boston, MA
  ...
  Ann H. Partridge, MD, MPH, Breast Oncology Center, Dana-Farber Cancer Institute, Boston, MA, Assistant Professor of Medicine, Harvard Medical School, Boston, MA
  ...
  Ann H. Partridge MD, MPH
  
  Breast Oncology Center

• 
  www.womenshealthissues.net/ms/news/612600/main.html - [Cached Version]
  Published on: 8/18/2008    Last Visited: 8/19/2008  

  "Many of these women are living as if they're waiting for the other shoe to drop," said lead researcher Dr. Ann Partridge, an oncologist at the Dana-Farber Cancer Institute and Brigham & Women's Hospital, in Boston.
  ...
  SOURCES: Ann Partridge M.D., MPH, oncologist, Dana-Farber Cancer Institute, Brigham & Women's Hospital, and assistant professor, medicine, Harvard Medical School, all in Boston; Michael Stefanek, Ph.D., vice president, behavioral research, American Cancer Society, Atlanta; H. Gilbert Welch, M.D., MPH, Veterans Affairs Outcomes Group, Department of Veterans Affairs Medical Center, White River Junction, Vt., and professor, medicine, Dartmouth Medical School; Feb. 12, 2008, Journal of the National Cancer Institute, online

• 
  www.markkosinsmd.com/PatientPortal/Public/NewsDetails.a - [Cached Version]
  Published on: 9/24/2008    Last Visited: 10/1/2008  

  "They have debunked the commonly held belief that age alone is a risk factor for recurrence after treatment of DCIS," said Dr. Ann Partridge, a medical oncologist and researcher at the Dana-Farber Cancer Institute and Brigham and Women's Hospital, in Boston.
  
  Partridge has published about women's anxiety over their prognosis when diagnosed with a DCIS.She found that women are typically highly anxious, even though their risk of recurrence or of developing invasive breast cancer is low.
  
  "I think this is a good study," Partridge said, although it does have limitations.For instance, she said, it is a single-institution study.However, Fox Chase physicians "are doing what they should be doing," Partridge said, explaining that the institution is careful about selecting the right treatment for the right patients, based on the characteristics of their cancer.

• 
  www.insidermedicine.com/archives/In_the_Spotlight_-_Dr_ - [Cached Version]
  Published on: 8/18/2008    Last Visited: 8/18/2008  

  In the Spotlight - Dr. Ann Partridge, MD, MPH
  ...
  In the Spotlight - Dr. Ann Partridge, MD, MPH
  
  (April 16, 2008 - Insidermedicine) On a recent trip to Boston, we caught up with Dr. Ann Partridge, MD, MPH, a Medical Oncologist at Dana-Farber Cancer Institute, and an Assistant Professor at Harvard Medical School.
  ...
  In the Spotlight - Dr. Ann Partridge, MD, MPH

Page:  1 2 3 4 5